Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Summary

The purpose of this phase I/II trial is to evaluate the safety and feasibility of azeliragon in patients with metastatic pancreatic cancer who did not respond to their first-line or second-line treatment.

General Information

NCT#: NCT05766748
Study ID: CAN-201 MPC
Trial Phase: Phase I/II

Trial Sponsor: Cedars-Sinai Medical Center, Cantex Pharmaceuticals
Therapies Used in This Trial: Azeliragon

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search